» Articles » PMID: 24573553

Imaging the Norepinephrine Transporter in Neuroblastoma: a Comparison of [18F]-MFBG and 123I-MIBG

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2014 Feb 28
PMID 24573553
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The norepinephrine transporter (NET) is a critical regulator of catecholamine uptake in normal physiology and is expressed in neuroendocrine tumors like neuroblastoma. Although the norepinephrine analog, meta-iodobenzylguanidine (MIBG), is an established substrate for NET, (123)I/(131)I-MIBG has several clinical limitations for diagnostic imaging. In the current studies, we evaluated meta-[(18)F]-fluorobenzylguanidine ([(18)F]-MFBG) and compared it with (123)I-MIBG for imaging NET-expressing neuroblastomas.

Experimental Design: NET expression levels in neuroblastoma cell lines were determined by Western blot and (123)I-MIBG uptake assays. Five neuroblastoma cell lines and two xenografts (SK-N-BE(2)C and LAN1) expressing different levels of NET were used for comparative in vitro and in vivo uptake studies.

Results: The uptake of [(18)F]-MFBG in cells was specific and proportional to the expression level of NET. Although [(18)F]-MFBG had a 3-fold lower affinity for NET and an approximately 2-fold lower cell uptake in vitro compared with that of (123)I-MIBG, the in vivo imaging and tissue radioactivity concentration measurements demonstrated higher [(18)F]-MFBG xenograft uptake and tumor-to-normal organ ratios at 1 and 4 hours after injection. A comparison of 4 hours [(18)F]-MFBG PET (positron emission tomography) imaging with 24 hours (123)I-MIBG SPECT (single-photon emission computed tomography) imaging showed an approximately 3-fold higher tumor uptake of [(18)F]-MFBG, but slightly lower tumor-to-background ratios in mice.

Conclusions: [(18)F]-MFBG is a promising radiopharmaceutical for specifically imaging NET-expressing neuroblastomas, with fast pharmacokinetics and whole-body clearance. [(18)F]-MFBG PET imaging shows higher sensitivity, better detection of small lesions with low NET expression, allows same day scintigraphy with a shorter image acquisition time, and has the potential for lower patient radiation exposure compared with (131)I/(123)I-MIBG.

Citing Articles

PET reporter systems for the brain.

Nerella S, Michaelides M, Minamimoto T, Innis R, Pike V, Eldridge M Trends Neurosci. 2023; 46(11):941-952.

PMID: 37734962 PMC: 10592100. DOI: 10.1016/j.tins.2023.08.007.


CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.

Grand-Guillaume J, Mansi R, Gaonkar R, Zanger S, Fani M, Eugster P J Transl Med. 2023; 21(1):604.

PMID: 37679770 PMC: 10485979. DOI: 10.1186/s12967-023-04466-z.


[F]MFBG PET/CT outperforming [I]MIBG SPECT/CT in the evaluation of neuroblastoma.

Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J Eur J Nucl Med Mol Imaging. 2023; 50(10):3097-3106.

PMID: 37160439 DOI: 10.1007/s00259-023-06221-4.


IMMUNOHISTOCHEMICAL MARKERS AND SPECT/CT SOMATOSTATIN-RECEPTOR (99MTC-TEKTROTYD) UPTAKE IN WELL AND MODERATELY DIFFERENTIATED NEUROENDOCRINE TUMORS.

Badan M, Piciu D Acta Endocrinol (Buchar). 2023; 18(4):523-530.

PMID: 37152876 PMC: 10162825. DOI: 10.4183/aeb.2022.523.


The Impact of PET/CT on Paediatric Oncology.

Brink A, Hlongwa K, More S Diagnostics (Basel). 2023; 13(2).

PMID: 36673002 PMC: 9857884. DOI: 10.3390/diagnostics13020192.


References
1.
Sisson J, Yanik G . Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors. Semin Nucl Med. 2012; 42(3):171-84. DOI: 10.1053/j.semnuclmed.2011.11.004. View

2.
Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

3.
Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

4.
Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B . Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009; 94(12):4757-67. PMC: 2795662. DOI: 10.1210/jc.2009-1248. View

5.
Sharp S, Shulkin B, Gelfand M, Salisbury S, Furman W . 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009; 50(8):1237-43. DOI: 10.2967/jnumed.108.060467. View